FDA Places Bacillus Protein Test Into Class II
Published Date: 6/22/2026
Rule
Summary
The FDA is officially putting a simple test that spots proteins from Bacillus bacteria in human samples into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and works well while speeding up patient access to cool new medical tools. The new rules kicked in on June 22, 2026, but have been in effect since February 3, 2023, making life simpler for device makers and patients alike.
Analyzed Economic Effects
5 provisions identified: 2 benefits, 2 costs, 1 mixed.
Design Verification and Clinical Study Rules
FDA requires manufacturers to provide detailed design description and documentation of analytical studies (e.g., limit of detection, inclusivity, cross-reactivity) and clinical studies or equivalent data sets comparing performance to an FDA-appropriate reference method (see 21 CFR 866.3046(b)(4)).
Class II Reclassification Speeds Access
The FDA classified the simple in vitro diagnostic test for detecting secreted proteins from Bacillus species into Class II (special controls). The agency says this Class II classification provides reasonable assurance of safety and effectiveness and will enhance patient access and reduce regulatory burdens; the order is effective June 22, 2026 (and was applicable on February 3, 2023).
Premarket 510(k) Requirement Remains
FDA stated that simple IVDs for detection of secreted proteins from Bacillus spp. are subject to premarket notification under section 510(k) and have not been exempted under section 510(m). Manufacturers must submit a 510(k) to market these Class II devices.
Prescription-Only and Lab Distribution Limits
FDA says these simple Bacillus-protein IVDs are prescription in vitro diagnostic devices and limits their distribution to laboratories that follow public health biosafety guidelines. The labeling must include statements that testing is for presumptive identification and that results require confirmation and reporting to public health authorities.
Detailed Labeling Requirements Imposed
The final order lists extensive labeling requirements that manufacturers must include (e.g., intended use details, sample types, population, warnings that results are presumptive, instructions to minimize exposure and contamination, and reporting instructions). These labeling requirements are codified at 21 CFR 866.3046(b)(3).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12445 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Traction Device
The FDA is officially putting the endoscopic traction device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while making it easier for patients to get access to this cool medical tool. The new rules took effect on June 22, 2026, and could speed up innovation without extra costs for makers.
2026-12367 — Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams
Epizyme, Inc. has asked the FDA to withdraw approval for their cancer drug TAZVERIK (200 mg tablets), effective June 22, 2026. This means TAZVERIK will no longer be officially approved for treating certain sarcomas and lymphomas, affecting patients and healthcare providers relying on it. The change might impact treatment options and insurance coverage, so folks should check with their doctors about next steps.
2026-12444 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Light-Projecting Measuring Device
The FDA is officially putting the endoscopic light-projecting measuring device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to cool new tech. The new rules took effect June 22, 2026, and could save time and money for makers and users alike.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
Previous / Next Documents
Previous: 2026-12432 — Safety Zone; Offshore, Ritidian Point, GU
The Coast Guard is setting up a temporary safety zone in the waters off Ritidian Point, Guam, from June 30 to July 1, 2026. This zone keeps boats and people out during a big missile defense exercise to keep everyone safe. If you want to enter, you’ll need special permission, but no extra costs or long delays are expected.
Next: 2026-12444 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Light-Projecting Measuring Device
The FDA is officially putting the endoscopic light-projecting measuring device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to cool new tech. The new rules took effect June 22, 2026, and could save time and money for makers and users alike.